The inspection was concluded on 14 February 2020.
Granules India in an exchange filing on Saturday said that US Food & Drug Administration (US FDA) has completed inspection of the facility located in Gagillapur, Hyderabad on 14 February 2020. The inspection was concluded with two observations.The company assured that it will respond to these observations within stipulated time.
Commenting on the US FDA Audit, Krishna Prasad, Chairman and Managing director, Granules India said, We successfully completed an FDA audit with two observations, which are being addressed and will respond to the FDA within the stipulated time. These observations will not affect the business continuity.
Shares of Granules India were trading 1.05% higher at Rs 177.5 on BSE.
Granules India is a growing pharmaceutical manufacturing company. The company produces finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
